ALVR241220P5000
- 0.00
- 0.000.00%
AlloVir Newsroom
Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty
Morgan Stanley Maintains AlloVir(ALVR.US) With Sell Rating, Maintains Target Price $0.5
Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)
Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)
Maintaining a Hold: AlloVir's Strategic Uncertainty and Financial Outlook
Analysts' Opinions Are Mixed on These Healthcare Stocks: Karuna Therapeutics (KRTX), AlloVir (ALVR) and Top Glove Bhd (OtherTGLVY)
B of A Securities Downgrades AlloVir to Underperform, Lowers Price Target to $1
AlloVir Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), AlloVir (ALVR) and Bristol-Myers Squibb (BMY)
Hold Rating on AlloVir Following Posoleucel Program Discontinuation and Strategic Shift
Piper Sandler Downgrades AlloVir to Neutral, Lowers Price Target to $1.5
AlloVir Analyst Ratings
AlloVir's Positive Strides in T-Cell Therapy Development and Promising 3Q23 Financial Performance: A Buy Rating Analysis
Piper Sandler Keeps Their Buy Rating on AlloVir (ALVR)
B of A Securities Initiates Coverage On AlloVir With Buy Rating, Announces Price Target of $17
AlloVir Analyst Ratings
Bank of America Securities Initiates a Buy Rating on AlloVir (ALVR)
AlloVir Analyst Ratings
Analysts Offer Insights on Healthcare Companies: AlloVir (ALVR), Cytokinetics (CYTK) and Guardant Health (GH)
SVB Securities Reaffirms Their Buy Rating on AlloVir (ALVR)